Addressing Disease Progression in CNS: Moving from Rare to Common Disorders

Time: 8:40 am

Details:

  • How are development paths for more common disease best managed?
  • Key areas of challenge with conducting trials
  • Are endpoints for gene therapies the same as endpoints for small molecules?

Speakers: